BEAM Latest Press Releases

-- October 27, 2026 --

Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress Globe Newswire 7:00 AM

-- October 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PRNewswire 10:02 AM

-- October 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM Globe Newswire 6:03 PM

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress Globe Newswire 7:00 AM

-- October 8, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PRNewswire 10:02 AM

-- September 24, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PRNewswire 5:35 PM

-- September 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM Globe Newswire 6:17 PM

-- September 16, 2026 --

BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law Business Wire 7:46 PM

-- September 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM Globe Newswire 5:13 PM

-- September 10, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PRNewswire 7:20 PM

-- September 8, 2026 --

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 Globe Newswire 6:00 AM

-- September 1, 2026 --

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer Globe Newswire 7:00 AM

-- August 31, 2026 --

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences Globe Newswire 7:00 AM

-- August 4, 2026 --

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Globe Newswire 7:00 AM

-- July 23, 2026 --

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Globe Newswire 7:00 AM

-- June 18, 2026 --

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes